Roche's Bid for Illumina Likely to Increase, Other Suitors May Emerge, Analysts Say | GenomeWeb

By Julia Karow

This article, originally posted Jan. 26, has been updated with information from additional analyst reports.

Roche is likely to increase its bid for Illumina, and other suitors of the sequencing and array firm may appear on the scene, according to research analysts commenting on Roche's hostile takeover bid for Illumina earlier last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.